Drugs / Vaginal Lactobacillus Dual Probiotic Capsules
Vaginal Lactobacillus Dual Probiotic Capsules
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07418918 | Jan → Sep 2023 | bacterial vaginosis | Guangdong Longchuangji Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07418957 | Jun 2024 → May 2025 | bacterial vaginosis | Guangdong Longchuangji Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vaginal Lactobacillus Dual Probiotic Capsules | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07418918 ↗ |
| Modality | Other / unclassified | “dual - live Lactobacilli-containing vaginal capsule” NCT07418918 ↗ |
| Route | Other | “dual - live Lactobacilli-containing vaginal capsule” NCT07418918 ↗ |